Evidence map›Paper›PMID 34673642›Full record

ArticleRespiration; international review of thoracic diseases2022

Coronavirus Disease 2019: COSeSco - A Risk Assessment Score to Predict the Risk of Pulmonary Sequelae in COVID-19 Patients.

Marina Aiello, Laura Marchi, Luigino Calzetta, Silvia Speroni, Annalisa Frizzelli, Marianna Ghirardini, Valentina Celiberti, Nicola Sverzellati, Maria Majori, Pier Anselmo Mori and 5 more

Open access · bronzeAbstract readComment
In one paragraph

Article in Respiration; international review of thoracic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Comparison of Long COVID-19 Caused by Different SARS-CoV-2 Strains: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  3. ESCMID rapid guidelines for assessment and management of long COVID.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Guideline
  4. Article
  5. Article
  6. Article
  7. A Key to Unlocking the Mysteries of COVID-19 Pulmonary Sequelae: Are We There?Respiration; international review of thoracic diseases · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Marina AielloDepartment of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
Laura MarchiDepartment of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
Luigino CalzettaDepartment of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
Silvia SperoniDepartment of Medicine and Surgery, Occupational Medicine Unit, University of Parma, Parma, Italy.
Annalisa FrizzelliDepartment of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
Marianna GhirardiniDepartment of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
Valentina CelibertiDepartment of Medicine and Surgery, Occupational Medicine Unit, University of Parma, Parma, Italy.
Nicola SverzellatiDepartment of Medicine and Surgery, Section of Radiology, Unit of Surgical Sciences, University of Parma, Parma, Italy.
Maria MajoriCardio-Thoracic-Vascular Department, Unit of Pulmonology and Thoracic Endoscopy, University Hospital of Parma, Parma, Italy.
Pier Anselmo MoriCardio-Thoracic-Vascular Department, Unit of Pulmonology and Thoracic Endoscopy, University Hospital of Parma, Parma, Italy.
Silvia RanzieriDepartment of Medicine and Surgery, Occupational Medicine Unit, University of Parma, Parma, Italy.
Roberta PisiDepartment of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
Giovanna PelàDepartment of Medicine and Surgery, and Department of General and Specialistic Medicine, University-Hospital of Parma, University of Parma, Parma, Italy.
Massimo CorradiDepartment of Medicine and Surgery, Occupational Medicine Unit, University of Parma, Parma, Italy.
Alfredo ChettaDepartment of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
University of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe presence of interstitial pneumonia in coronavirus disease 2019 (COVID-19) patients, as diagnosed through laboratory, functional, and radiological data, provides potential predicting factors of pulmonary sequelae.

objectivesThe objectives were the creation of a risk assessment score for pulmonary sequelae at high-resolution computed tomography (HRCT) through the assessment of laboratory data, lung function, and radiological changes in patients after the onset of COVID-19 interstitial pneumonia and the identification of predictive factors.

methodsWe enrolled 121 subjects hospitalized due to COVID-19 pneumonia in our study. Clinical features, Charlson Comorbidity Index (CCI) score, HRCT score, and blood chemistry data at hospital admission, as well as HRCT score, pulmonary function testing values, exercise capacity by means of a 6-Minute Walk Test (6MWT), and dyspnea perception by the modified Medical Research Council (mMRC) at 4-month follow-up, were all recorded. The variables were elaborated in order to create a predictive model to identify patients at high risk of pulmonary sequelae at HRCT.

resultsAt the time of follow-up visit, 63% of patients had functional abnormality (diffusion lung capacity and/or total lung capacity <80% of predicted). Age, BMI, CCI, D-dimer, 6MWT, and mMRC were included in the COVID-19 Sequelae Score (COSeSco, ranging 0-15), which was able to individuate COVID-19 patients with radiologic sequelae (HRCT score >10%) at follow-up. The most revelatory COSeSco value that was found to intercept the highest sensitivity (100%) and specificity (77%) was 2.

conclusionThe COSeSco - comprising age, BMI, comorbidities, D-dimer, walking distance, and dyspnea perception - makes it possible to identify particularly at-risk COVID-19 patients who are likely to develop pulmonary sequelae assessed by HRCT.

Indexed as

COVID-19HumansLungRespiratory Function TestsRisk AssessmentSARS-CoV-2Coronavirus disease 2019Diffusion capacityLong COVIDLung function

Identifiers

PMID34673642
PMCPMC9059039
OpenAlexW3206995628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.